Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Vistagen Therapeutics › Commodore Capital LP cut its VTGN stake below 5% (3.7%) Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 16, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0001831942-26-000051
Data quality Verified: identifiers matched exactly
Around the same time Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 4, 2026 Company filing · Form 8-K · Listing notice Received a notice from its stock exchange “On August 4, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) received an extension notification (the “ Extension Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) granting the Company a 180-day extension, until February 1, 2027 (the “ Extension Period ”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“ Common Stock…” Aug 14, 2026 Company filing · Form 8-K · Results Reported its results What came next Oct 7, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On October 7, 2026, the Board of Directors (the “ Board ”) of Vistagen Therapeutics, Inc. (the “ Company ”) approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, which was originally adopted effective August 11, 2026 and described in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026 (as amended and restated, the “ Plan ”).” Oct 26, 2026 Company filing · Form 8-K · Restructuring, Other news Announced job cuts, closures or a restructuring, and reported other company news “On October 26, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate capabilities required for U.S. registration-directed Phase 3 development of fasedienol, its lead clinical-stage product candidate for treatment of social anxiety disorder, as well as potential future development of…” Nov 13, 2026 Company filing · Form 8-K · Results Reported its results Nov 16, 2026 5% stake Commodore Capital LP reported a passive stake (13G) of 3.7% Nov 16, 2026 5% stake BVF PARTNERS L P/IL reported a passive stake (13G) of 3.7%